| NCT06981338 | Guttmann NeuroRecovery - Viability, Safety, and Efficacy of Intrathecal Wharton's Jelly Mesenchymal Stem Cells and Transcutaneous Spinal Cord Stimulation in Chronic Spinal Cord Injury Rehabilitation | Institut Guttmann | | - Age 16 - 70 yrs
- Level C1-T12
AIS A, B, C- 1 years - 5 years
| Recruiting soon | 10 | PHASE1, PHASE2 | Biological/cell based | General health | - Adverse Events (AEs)
- American Spinal Injury Association Impairment Scale (AIS): International Standards for Neurological Classification of Spinal Cord Injury (ISNCSCI)
- International Standards to Autonomic Function after SCI (ISAFSCI)
- Motor Evoked Potentials (MEPs)
- Sensory evoked potentials (including mixed and dermatomal, mSSEPs, dSSEPs, contact heat/laser evoked potentials- CHEPS/LEPs)
| 2 years | 01 September 2025 | 20 May 2025 | 1 | |
| NCT07024407 | A Study of Andecaliximab in People With Spinal Cord Injury at Risk for Bone Growth Outside of the Normal Skeleton. | Ashibio Inc | | - Age 18 - 89 yrs
- Level C1-S5
AIS - ≥ 10 days
| Recruiting | 10 | PHASE1, PHASE2 | Drug | General health | | 13 weeks | 14 May 2025 | 17 June 2025 | 1 | |
| NCT06828653 | Comparing Digitally and Traditionally Made Ankle Foot Orthoses | Holland Bloorview Kids Rehabilitation Hospital | | - Age ≥ 8 yrs
- Level C1-S5
AIS - All
- Require the use of an AFO to improve physical functioning
- Be able to ambulate independently
- Meet requirements for AFO funding by the Assistive Device Program in Ontario, Canada
| Recruiting | 50 | NA | Technology | Standing/walking/mobility | - 10 Meter Walking Test (10 MWT)
- Goal Attainment Scaling (GAS) score
- Quebec User Evaluation of Satisfaction with Assistive Technology (QUEST)
- Timed Up and Go Test (TUG)
| 14 weeks | 05 September 2025 | 14 February 2025 | 2 | |
| NCT06873776 | Arm and Leg Cycling for Accelerated SCI Recovery | Shirley Ryan AbilityLab | | - Age 18 - 75 yrs
- Level C1-T11
AIS C, D- ≥ 1 years
- Be able to ambulate independently for at least 10 meters
- Ambulate with maximum walking speed of less than 0.8 meters/second
- Have bilateral arm strength to independently arm cycle 15 minutes
| By invitation | 40 | NA | Rehabilitation | Standing/walking/mobility | - 10 Meter Walking Test (10 MWT)
- 6-Minute Walk Test (6MWT)
- Ashworth and Modified Ashworth Scale (MAS)
- Berg Balance Scale (BBS)
- Motor Evoked Potentials (MEPs)
- Sensory evoked potentials (including mixed and dermatomal, mSSEPs, dSSEPs, contact heat/laser evoked potentials- CHEPS/LEPs)
- Surface Electromyography (sEMG)
- Walking Index for Spinal Cord Injury (WISCI) and WISCI II
| 6 months | 01 December 2025 | 13 March 2025 | 1 | |
| NCT06922890 | First-in-Human Clinical Trial of STUP-001, an In Vivo Direct Cell Conversion Gene Therapy for AIS-A/B Chronic Spinal Cord Injury | Yonsei University | | - Age 19 - 60 yrs
- Level C1-S5
AIS A, B- ≥ 6 months
- Be able to undergo general anesthesia
- Be able to provide evidence of non-fertile status, if female
- NOT have significant contraindications for elective surgery
- NOT have a history of malignancy within the previous 5 years
| Recruiting | 9 | PHASE1, PHASE2 | Drug | General health | | 7 months | 30 July 2025 | 11 April 2025 | 2 | |
| NCT06978205 | Effect of Urethral Balloon Dilatation on Urinary Retention After Spinal Cord Injury | Qilu Hospital of Shandong University | | - Age 18 - 80 yrs
- Level C1-S5
AIS - All
- Have urinary retention with post-void residual volume more than 300ml
- Have urodynamic evidence of maximal urethral pressure >50cmH2O
- NOT use an indwelling urinary catherter for bladder management
- NOT have a urinary tract infection
| Recruiting | 74 | NA | Technology | Bladder health/function | - Hospital Anxiety and Depression Scale (HADS)
- Neurogenic Bladder Symptom Score
- Qualiveen
| 3 weeks | 28 April 2025 | 18 May 2025 | 1 | |
